NCT07630246Not yet recruiting
CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS
UNCOVERING THE GENETIC LANDSCAPE OF LUNG ADENOCARCINOMA: A CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS
Source: ClinicalTrials.gov · Last updated 5 Jun 2026
Brief summary (registry, in English)
Lung cancer remains a significant challenge in oncology, with poor prognosis for patients, especially those with advanced-stage disease. The phenomenon of tumor spread through air spaces (STAS) in pulmonary cancer has garnered attention for its association with aggressive tumor behavior and adverse clinical outcomes. Spread through air spaces identification has been highly debatable on scientific community as an important prognostic feature for distant and locoregional recurrence and as a key player in the differential diagnosis and selection of the appropriate treatment. The aim of this study is to unravel the complexities of STAS-positive lung adenocarcinoma (LUAD) diagnosis and treatment options. For that, we intend to (1) isolate primary lung cancer tissues from early-stages lung adenocarcinoma to fabricate organoid in vitro models and (2) evaluate the microRNA (miRNA) profile of tumor and healthy tissue samples. This is a Hybrid (prospective and retrospective) observational clinical study with a nested translational study.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 140 (estimated)
- First submitted
- 1 Jun 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- Universidade Nova de Lisboa
- Diseases
- Lung cancer
- NCT number
- NCT07630246
What you commit to
- Study type: Observational
- Planned participants: 140
- From 1 Jun 2026 to the primary completion date, 30 Jun 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment for LUAD
Other illness
- History of inflammatory bowel disease and autoimmune diseases
- History of hepatic disease (including history of alcoholic or viral hepatitis)
- LUAD patients with other active malignancy(ies)
Other
- Incapability of understanding the study and/or providing consent
- Signed informed consent unavailable
Who the study is looking for
- Patients older than 18 years old
- Active early LUAD diagnosis according to the American Joint Committee on Cancer
- Signed informed consent or previous consent given for future research
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NMS Research | Cancer Nanomedicine - João Conde's Lab Coordinator of this site? Confirm its status | Lisbon | Portugal | Unknown status |
| Unidade Local de Saúde de São José Coordinator of this site? Confirm its status | Lisbon | Portugal | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.